SeekingAlpha · Sep 12, 2026
ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
2026-09-12. The following slide deck was published by ADC Therapeutics SA in conjunction with this event.
AD
NASDAQ · ADCT
ADC Therapeutics S.A.
Healthcare · Biotechnology
$1.05
Down-$0.04 (-3.67%)
Updated Sep 17, 2026, 2:18 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 507.9M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $0.78 – $4.98
- Volume
- 3.32M
- Avg. volume
- 1.16M
Price performance
ADCT price history
1M range · 20 trading sessions · Daily adjusted prices
ADCT closed at $1.05 after 20 trading sessions, up 0.96% for the selected period.
- Last close
- $1.05
- Period change
- +0.96%
- Period low
- $0.96
- Period high
- $1.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.09 | $1.095 | $1.025 | $1.05 | 3.32M |
| Sep 15, 2026 | $1.12 | $1.12 | $1.03 | $1.09 | 1.26M |
| Sep 14, 2026 | $1.07 | $1.12 | $1.06 | $1.11 | 808.48K |
| Sep 11, 2026 | $1.13 | $1.156 | $1.04 | $1.07 | 989.11K |
| Sep 10, 2026 | $1.21 | $1.24 | $1.07 | $1.11 | 957.19K |
| Sep 9, 2026 | $1.28 | $1.31 | $1.191 | $1.22 | 1.71M |
| Sep 8, 2026 | $1.33 | $1.35 | $1.27 | $1.30 | 930.76K |
| Sep 4, 2026 | $1.30 | $1.37 | $1.30 | $1.36 | 1.48M |
| Sep 3, 2026 | $1.32 | $1.37 | $1.30 | $1.32 | 2.77M |
| Sep 2, 2026 | $1.23 | $1.35 | $1.23 | $1.32 | 1.96M |
| Sep 1, 2026 | $1.15 | $1.24 | $1.14 | $1.24 | 1.15M |
| Aug 31, 2026 | $1.13 | $1.19 | $1.125 | $1.17 | 1.25M |
| Aug 28, 2026 | $1.11 | $1.17 | $1.07 | $1.14 | 2.58M |
| Aug 27, 2026 | $1.05 | $1.14 | $1.05 | $1.12 | 1.4M |
| Aug 26, 2026 | $1.04 | $1.075 | $1.01 | $1.05 | 1.95M |
| Aug 25, 2026 | $0.9755 | $1.05 | $0.96 | $1.04 | 3.93M |
| Aug 24, 2026 | $0.99 | $1.00 | $0.9514 | $0.9651 | 640.51K |
| Aug 21, 2026 | $0.974 | $1.00 | $0.97 | $0.9966 | 1.09M |
| Aug 20, 2026 | $1.02 | $1.04 | $0.9497 | $0.9601 | 2.42M |
| Aug 19, 2026 | $1.05 | $1.09 | $1.015 | $1.04 | 1.9M |
Latest ADCT news
The latest Smart Investors Daily articles mentioning ADCT.
Stock researchCompany · Overview
ADCT research
Overview
Company profile and research snapshot.
Company profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Guggenheim | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 4, 2026 | RBC Capital | Sector Perform | — |
| May 5, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m. ET.
Fintel · Aug 28, 2026
ADC Therapeutics (ADCT) Price Target Increased by 43.18% to 2.68
Yahoo · Aug 27, 2026
ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses
On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company’s confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main efficacy bar, but the FDA has flagged serious safety concerns about the combination that could complicate its path to a fuller […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
